Trial reportDiabetes care2008
Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy.
Trial report in Diabetes care, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 81 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus
The Effects of Co-administration of Colesevelam and Sitagliptin on Glucose Metabolism in Patients With Type 2 Diabetes
24 Week Open Label, Single Arm Study of Colesevelam in High Risk South Asians With Suboptimal LDL-c Levels Despite Maximally Tolerated Statin Therapy
Who cites it
81 citing papers in PubMed, 1 synthesis or guideline pooled it, 246 citations in OpenAlex.
- Colesevelam for type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2012Pooled it
- Effect of colesevelam HCl monotherapy on lipid particles in type 2 diabetes mellitus.Cardiovascular drugs and therapy · 2014Trial
- The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes.Diabetes · 2013 · on this mapTrial
- Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and β-cell function.Diabetes care · 2012Trial
- Trial
- Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus.Diabetes, obesity & metabolism · 2012Trial
- Association of fructosamine to indices of dyslipidemia in older adults with type 2 diabetes.Diabetes & metabolic syndromeTrial
- The Gut-Liver Axis in MASLD: From Host-Microbiome Crosstalk to Precision Therapeutics.Microorganisms · 2026Review
- Empowering Pharmacists in Type 2 Diabetes Care: Opportunities for Prevention, Counseling, and Therapeutic Optimization.Journal of clinical medicine · 2025Article
- Host response to cholestyramine can be mediated by the gut microbiota.Microbiome research reports · 2024Article
- Preparation of cholesterol-imprinted polymer for selective adsorption of cholesterol from gastrointestinal mimicking solution.Turkish journal of chemistry · 2024Article
- Bile Acid Sequestrants Based on Natural and Synthetic Gels.Gels (Basel, Switzerland) · 2023Review
- Bile acids and microbes in metabolic disease.World journal of gastroenterology · 2022Review
- Type 2 Diabetes and the Microbiome.Journal of the Endocrine Society · 2022Review
- Role of Bile Acids in the Regulation of Food Intake, and Their Dysregulation in Metabolic Disease.Nutrients · 2021Review
- Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work.European journal of medicinal chemistry · 2019Review
- Metabolic Effects of Bile Acids: Potential Role in Bariatric Surgery.Cellular and molecular gastroenterology and hepatology · 2019Review
- Intestinal bile acid sequestration improves glucose control by stimulating hepatic miR-182-5p in type 2 diabetes.American journal of physiology. Gastrointestinal and liver physiology · 2018Article
- Bile acid signaling and bariatric surgery.Liver research (Beijing, China) · 2017Article
- Pharmabiotics as an Emerging Medication for Metabolic Syndrome and Its Related Diseases.Molecules (Basel, Switzerland) · 2017Review
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHyperglycemia is a risk factor for microvascular complications and may increase the risk of cardiovascular disease in patients with type 2 diabetes. This study tested the LDL cholesterol-lowering agent colesevelam HCl (colesevelam) as a potential novel treatment for improving glycemic control in patients with type 2 diabetes on sulfonylurea-based therapy. RESEARCH DESIGN AND
methodsA 26-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter study was carried out between August 2004 and August 2006 to evaluate the efficacy and safety of colesevelam for reducing A1C in adults with type 2 diabetes whose glycemic control was inadequate (A1C 7.5-9.5%) with existing sulfonylurea monotherapy or sulfonylurea in combination with additional oral antidiabetes agents. In total, 461 patients were randomized (230 given colesevelam 3.75 g/day and 231 given placebo). The primary efficacy measurement was mean placebo-corrected change in A1C from baseline to week 26 in the intent-to-treat population (last observation carried forward).
resultsThe least squares (LS) mean change in A1C from baseline to week 26 was -0.32% in the colesevelam group and +0.23% in the placebo group, resulting in a treatment difference of -0.54% (P < 0.001). The LS mean percent change in LDL cholesterol from baseline to week 26 was -16.1% in the colesevelam group and +0.6% in the placebo group, resulting in a treatment difference of -16.7% (P < 0.001). Furthermore, significant reductions in fasting plasma glucose, fructosamine, total cholesterol, non-HDL cholesterol, and apolipoprotein B were demonstrated in the colesevelam relative to placebo group at week 26.
conclusionsColesevelam improved glycemic control and reduced LDL cholesterol levels in patients with type 2 diabetes receiving sulfonylurea-based therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.